Overview

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Status:
Terminated

Trial end date:
2019-03-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Pembrolizumab